Optogenetik: Hücreleri Işıkla Kontrol Etmenin Nobel’i
The 2026 Nobel Prize in Physiology or Medicine recognized Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries concerning light-gated ion channels and optogenetics. The significance of their work goes beyond the striking idea of controlling cells with light. Optogenetics changed neuroscience by giving researchers a way to test causal relationships inside neural circuits rather than merely observing which regions or cells become active during a behaviour. The technique emerged from research on channelrhodopsins, light-sensitive proteins found in the single-celled green alga Chlamydomonas. When these proteins are genetically introduced into selected neurons, pulses of light can alter the cells’ electrical activity with millisecond-scale precision. Genetic targeting determines which cells receive the light-sensitive switch, while illumination controls when that switch is activated. This capability has transformed experiments on neural circuits involved in movement, learning, memory, emotion and disease. Its clinical translation, however, remains at an early stage. Human trials in advanced retinitis pigmentosa have begun testing whether surviving retinal cells can be made light-sensitive after photoreceptors have been lost. A 2026 study involving ten participants reported encouraging safety findings and meaningful increases in light sensitivity in six participants, but normal or high-resolution vision was not restored. The Nobel therefore recognizes a mature scientific revolution rather than a finished medical therapy. The next test is whether the extraordinary experimental precision of optogenetics can be translated into safe, durable and clinically useful interventions in humans.